Wells Fargo & Company Boosts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $95.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price hoisted by equities researchers at Wells Fargo & Company from $75.00 to $95.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price indicates a potential downside of 3.95% from the stock’s current price.

Several other research firms also recently issued reports on HALO. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 31st. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 target price on the stock in a research note on Friday. Finally, HC Wainwright increased their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $89.60.

Halozyme Therapeutics Trading Up 15.3%

Halozyme Therapeutics stock opened at $98.91 on Friday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The firm has a market cap of $11.73 billion, a price-to-earnings ratio of 34.86, a price-to-earnings-growth ratio of 0.35 and a beta of 0.85. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $96.77. The firm’s 50 day moving average price is $75.74 and its two-hundred day moving average price is $71.25.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts predict that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the transaction, the director directly owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,477 shares of company stock worth $5,102,643 in the last quarter. 2.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new position in Halozyme Therapeutics in the fourth quarter worth approximately $128,201,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $124,031,000. Voloridge Investment Management LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at approximately $77,587,000. Qube Research & Technologies Ltd bought a new stake in Halozyme Therapeutics in the second quarter worth approximately $51,295,000. Finally, Assenagon Asset Management S.A. grew its position in Halozyme Therapeutics by 4,578.9% in the second quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock worth $78,086,000 after acquiring an additional 976,321 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 results: Halozyme reported adjusted EPS of $2.28, above the roughly $1.79-$1.82 consensus range, while revenue reached $481 million versus estimates of approximately $402 million. Revenue increased 48% year over year, and royalty revenue rose 50% to $308 million. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised full-year guidance: The company now expects 2026 revenue of $1.835 billion-$1.910 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the approximately $8.02 analyst consensus, signaling stronger expected profitability and growth.
• Positive Sentiment: Additional collaboration momentum: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s recurring royalty and licensing growth strategy. Halozyme Collaboration Agreements
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO from “market perform” to “outperform” with a $110 price target. HC Wainwright also raised its target from $95 to $115 and maintained a “buy” rating, implying substantial upside from the current trading level. Benzinga Analyst Actions
• Neutral Sentiment: The company’s earnings-call presentation and transcript provide additional details on the quarter, collaboration pipeline and operating outlook. Q2 2026 Earnings Presentation

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.